Hoth Therapeutics expands Phase 2a of HT-001 trial for skin cancer

Hoth Therapeutics has received written approval from the GW University Hospital, UC Irvine and Northwell Health to proceed with its First-in-Human Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors. This Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.